Implementation and Assessment of Hyperglycemic Conditions for the Creation of a Diabetic Blood Vessel Mimic

Abstract

IMPLEMENTATION AND ASSESSMENT OF HYPERGLYCEMIC CONDITIONS FOR THE CREATION OF A DIABETIC BLOOD VESSEL MIMIC By Vikramaditya Mediratta Introduction: Diabetes Mellitus is a metabolic disorder that affects a person's ability to either produce insulin (Type I diabetes mellitus) or properly use insulin (Type II diabetes mellitus) in order to maintain adequate blood glucose levels. The most severe diabetic complications arise due to hyperglycemia-a state of extremely high blood glucose levels-such as, coronary artery disease (CAD), in which coronary stent therapy is a popular method of treatment. However, research has shown a high rate of in-stent restenosis in diabetic patients Experiment Glucose Added (g) Cell Media Volume (mL) Assumed Volume of Complete "Low Glucose" Cell Media (mL) Volume of Applied Glycemic Cell Media Solution (mL) Average Glucose Concentration of Wells (mg/dL) Adjusted Glucose Concentration of Wells (mg/dL) Summary of Conclusions from Experimentation with BAECs & HUVECs in 100 mg/dL & 400 mg/dL Environments

Development and Characterization of Tissue Engineered Blood Vessel Mimics Under "Diabetic" Conditions

“…Other cell sources have been used in BVM construction, including human coronary artery endothelial cells (HCAECs) and to a limited extent, diabetic human coronary artery endothelial cells (DHCAECs) [29]. The initial steps were taken to develop a "diabetic" blood vessel mimic through the development of media solutions of various glucose concentrations to replicate a hyperglycemic environment with bovine aortic endothelial cells (BAECs) and HUVECs [30]. From this study, it was determined that endothelial cells have increased glucose consumption when exposed to increased glucose concentrations in the cell media [30].…”

“…In the Cal Poly Tissue Engineering lab, blood vessel mimics are created to test intravascular devices in vitro. In order to facilitate testing of intravascular devices intended for use in diabetic patients, a diabetic BVM was previously created using diabetic human coronary artery endothelial cells (DHCAECs) and diabetic human coronary artery smooth muscle cells (DHCSMCs) [30,67]. Although this model demonstrated the ability to apply diseased cell types to the BVM set up, there was a lack of analysis to demonstrate if the diabetic BVM accurately modeled diabetic disease processes.…”